- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00077454
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
A Phase I Study of Single Agent OSI-774 (Tarceva) (NSC# 718781, IND# 63383) Followed by OSI-774 With Temozolomide for Patients With Selected Recurrent/Refractory Solid Tumors, Including Brain Tumors
Study Overview
Status
Conditions
- Recurrent Childhood Medulloblastoma
- Recurrent Childhood Ependymoma
- Recurrent Neuroblastoma
- Recurrent Osteosarcoma
- Recurrent Childhood Rhabdomyosarcoma
- Previously Treated Childhood Rhabdomyosarcoma
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Childhood Malignant Germ Cell Tumor
- Recurrent Childhood Cerebellar Astrocytoma
- Recurrent Childhood Cerebral Astrocytoma
- Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
- Recurrent Childhood Brain Tumor
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the maximum tolerated dose of erlotinib in children with recurrent or refractory solid tumors.
II. Determine the dose-limiting toxic effects of this drug alone and with temozolomide in these patients.
III. Determine the tolerability of this regimen in these patients. IV. Determine the pharmacokinetics of this regimen in these patients.
SECONDARY OBJECTIVES:
I. Determine, preliminarily, the antitumor activity of this regimen in these patients.
OUTLINE: This is a 2-part, multicenter, dose-escalation study of erlotinib. Patients are stratified according to pretreatment (heavily pretreated [received more than 2 prior multiagent myelosuppressive chemotherapy regimens OR received prior craniospinal or pelvic radiotherapy or bone marrow transplantation OR has bone marrow involvement] vs less heavily pretreated).Part 1:
Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib during course 1 only until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Part 2: Patients receive erlotinib (at the MTD) and temozolomide as in part 1.
PROJECTED ACCRUAL: A total of 9-45 patients (9-24 for part 1 and up to 21 for part 2) will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Arcadia, California, United States, 91006-3776
- COG Phase I Consortium
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
One of the following histologically confirmed solid tumors:
- Brain tumors
- Osteogenic sarcoma
- Rhabdomyosarcoma
- Soft tissue sarcoma (excluding Ewing's sarcoma)
- Neuroblastoma
- Germ cell tumors
- Recurrent or refractory disease
- No known curative therapy exists
- Performance status - Karnofsky 50-100% (for patients age 11 to 21)
- Performance status - Lansky 50-100% (for patients age 10 and under)
- At least 8 weeks
- Absolute neutrophil count > 1,000/mm^3
- Platelet count > 100,000/mm^3 (transfusion independent*)
- Hemoglobin > 8.0 g/dL (transfusion allowed)
- Bilirubin < 1.5 times upper limit of normal (ULN)
- ALT < 2.5 times ULN
- Albumin ≥ 2 g/dL
- Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min
Creatinine based on age as follows:
- ≤ 0.8 mg/dL for patients age 5 and under
- ≤ 1.0 mg/dL for patients 6 to 10
- ≤ 1.2 mg/dL for patients 11 to 15
- ≤ 1.5 mg/dL for patients age 15 to 21
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Able to swallow tablets (for patients in part 2 only)
- No uncontrolled infection
- Recovered from all prior immunotherapy
- At least 7 days since prior biologic therapy
- At least 3 months since prior stem cell transplantation and no evidence of active graft-versus-host disease
- More than 1 week since prior growth factors
- No concurrent prophylactic growth factor therapy
- No concurrent immunotherapy
- No concurrent biologic therapy
- More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered
- No other concurrent chemotherapy
No concurrent systemic corticosteroids except for treatment of increased intracranial pressure or symptomatic tumor edema in patients with CNS tumors
- No concurrent steroids as an antiemetic
- Concurrent dexamethasone for patients with CNS tumors allowed provided patient has been on a stable or decreasing dose for at least 1 week before study entry
- Recovered from all prior radiotherapy
- At least 2 weeks since prior local palliative radiotherapy (small port)
- At least 6 weeks since prior substantial bone marrow irradiation
- At least 6 months since prior craniospinal radiotherapy
- At least 6 months since prior radiotherapy to 50% or more of the pelvis
- At least 8 weeks since prior standard-fraction radiotherapy for patients with recurrent brain tumors unless there is biopsy proof of recurrent tumor
- Prior radiosurgery within the past 9 months allowed provided there is documentation of progressive disease by biopsy, positron-emission tomography (PET) scan, or MR spectroscopy
- No concurrent radiotherapy
- More than 1 week since prior CYP3A4 inhibitors
- More than 4 weeks since prior CYP3A4 inducers
- More than 5 days since prior proton-pump inhibitors
- More than 2 days since prior H_2 blockers
- No prior erlotinib
- No concurrent enzyme-inducing anticonvulsants
- No concurrent proton-pump inhibitors
- No concurrent H2 blockers
- No other concurrent investigational agents
- Concurrent antacids allowed provided the antacid is not administered 2 hours before, during, and 2 hours after erlotinib administration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (erlotinib hydrochloride, temozolomide)
Patients receive oral erlotinib once daily on days 1-28.
Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5.
Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Correlative studies
Other Names:
Given PO
Other Names:
Given orally (PO)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
Time Frame: 56 days (2 courses)
|
56 days (2 courses)
|
Maximum-tolerated dose (MTD) based on the incidence of DLT as assessed by NCI CTCAE version 3.0
Time Frame: 56 days (2 courses)
|
56 days (2 courses)
|
Pharmacokinetics of erlotinib hydrochloride
Time Frame: At baseline and at 0.5, 1, 2, 4, 6, 8, and 24 hours of course 1
|
At baseline and at 0.5, 1, 2, 4, 6, 8, and 24 hours of course 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Regina Jakacki, COG Phase I Consortium
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Glioma
- Neoplasms, Neuroepithelial
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neoplasms, Bone Tissue
- Neoplasms, Connective Tissue
- Neoplasms, Muscle Tissue
- Neuroectodermal Tumors, Primitive, Peripheral
- Myosarcoma
- Neoplasms
- Sarcoma
- Recurrence
- Brain Neoplasms
- Ependymoma
- Medulloblastoma
- Osteosarcoma
- Astrocytoma
- Neuroblastoma
- Rhabdomyosarcoma
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Rhabdomyosarcoma, Embryonal
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
- Temozolomide
Other Study ID Numbers
- NCI-2012-01808
- U01CA097452 (U.S. NIH Grant/Contract)
- ADVL0214
- CDR0000350336
- COG-ADVL0214
- NCI-04-C-0256
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Childhood Medulloblastoma
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Giant Cell Glioblastoma | Recurrent Childhood Glioblastoma | Recurrent Childhood Gliosarcoma | Recurrent Childhood OligodendrogliomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Ependymoma | Recurrent MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Childhood High-grade Cerebral Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood Cerebral Astrocytoma | Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor | Recurrent Childhood... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Brain Stem Glioma | Childhood Spinal Cord Neoplasm | Childhood Oligodendroglioma | Childhood Cerebral Anaplastic AstrocytomaUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)TerminatedRecurrent Childhood Medulloblastoma | Childhood Choroid Plexus Tumor | Childhood Ependymoblastoma | Childhood Grade III Meningioma | Childhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma | Childhood Medulloepithelioma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGlioma | Recurrent Childhood Medulloblastoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Diffuse Intrinsic Pontine Glioma | Refractory Brain Neoplasm | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Glioblastoma | Recurrent Primitive Neuroectodermal Tumor | Childhood Astrocytoma and other conditionsUnited States
-
Sabine Mueller, MD, PhDMayo Clinic; Vyriad, Inc.; No More Kids With Cancer; The Matthew Larson Foundation...CompletedMedulloblastoma Recurrent | Atypical Teratoid/Rhabdoid Tumor | Medulloblastoma, Childhood, RecurrentUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood Infratentorial Ependymoma | Childhood Supratentorial Ependymoma | Recurrent Childhood... and other conditionsUnited States
Clinical Trials on laboratory biomarker analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)Recruiting
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingLynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingRecurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingMalignant NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLung Cancer | Radiation Toxicity | Adult Brain TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin TumorUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed